Chemomab Therapeutics Q3 EPS $(0.63) Misses $(0.12) Estimate
Benzinga Newsdesk 8 hours ago
NewsEarningsEarnings Misses
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.63) per share which missed the analyst consensus estimate of $(0.12) by 472.73 percent. This is a 96.88 percent decrease over losses of $(0.32) per
Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.63) per share which missed the analyst consensus estimate of $(0.12) by 472.73 percent. This is a 96.88 percent decrease over losses of $(0.32) per share from the same period last year.
